GLP (Good Laboratory Practice) toxicology studies typically progress from rodents (usually rats) to non-rodent species (often dogs) for several important reasons:1. Species differences: Rats and dogs may metabolize drugs differently or show varied responses to compounds. Testing in both species provides a more comprehensive safety profile[2].2. Regulatory requirements: Many regulatory agencies require testing in both rodent and non-rodent species before human trials can begin. This helps identify potential toxicities that may be species-specific[2].3. Physiological similarities: Dogs share more physiological similarities with humans in certain aspects, making them a valuable model for predicting human responses[2].4. Dose extrapolation: Using two species allows for better dose extrapolation and safety margin calculations for human trials.5. Longer-term studies: Dogs have longer lifespans than rats, enabling extended toxicity studies that better mimic human drug use durations.6. Cardiovascular assessment: Dogs are particularly useful for evaluating cardiovascular effects of drugs, which is crucial for safety assessment[2].By testing in both rats and dogs, researchers can gather more comprehensive safety data, better predict potential human toxicities, and meet regulatory requirements for drug development.Sources[1] Central Nervous System GLP-1 Receptors Regulate Islet Hormone ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505222/[2] Preclinical GLP Neurotoxicology - MD Biosciences https://www.mdbneuro.com/glp-nonclinical-safety-neurotoxicology[3] 4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840795/[4] Simultaneous assessment of central nervous and respiratory ... https://www.sciencedirect.com/science/article/pii/S1056871923000199[5] Behavioral tests in rodent models of stroke - PMC - NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315143/
- Forums
- ASX - By Stock
- Ann: Brain Injury Program GLP Studies Further Update
NYR
nyrada inc.
Add to My Watchlist
10.6%
!
26.0¢

GLP (Good Laboratory Practice) toxicology studies typically...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
26.0¢ |
Change
0.025(10.6%) |
Mkt cap ! $54.83M |
Open | High | Low | Value | Volume |
23.5¢ | 26.5¢ | 23.5¢ | $352.7K | 1.440M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3600 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 4499 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3600 | 0.240 |
5 | 169261 | 0.235 |
5 | 94773 | 0.220 |
2 | 120005 | 0.215 |
7 | 419378 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 4499 | 1 |
0.265 | 154139 | 2 |
0.270 | 40000 | 1 |
0.275 | 405 | 1 |
0.280 | 117907 | 3 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
NYR (ASX) Chart |
The Watchlist
CDE
CODEIFAI LIMITED
John Houston / Martin Ross, Executive Chairman / COO
John Houston / Martin Ross
Executive Chairman / COO
Previous Video
Next Video
SPONSORED BY The Market Online